23 October 2024 Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had.
German pharma major Bayer is among the four latest companies named and shamed for breaching the Code of Practice of the Association of the British Pharmaceutical Industry (ABPI). 12 December 2017
Privately-held drugmaker Consilient Health has revealed the UK’s health technology assessor NICE has rejected its appeal against July’s negative reimbursement decision for its obesity med Mysimba. 12 December 2017
Swiss oncology giant Roche has revealed positive results from the Phase III IMmotion151 study of Tecentriq and Avastin in kidney cancer. 12 December 2017
Drugs that prove to be an effective treatment for migraines could find their way into the hands of as many as 13% of Americans, so it is no surprise that several of pharma’s biggest players are in the race to gain a share of the market. 12 December 2017
In yet another licensing deal, UK-based Mundipharma has expanded its ophthalmology portfolio in the Middle East and Africa by agreeing a new commercial partnership with NTC, an Italian pharmaceutical company with deep experience in research and development, to license and distribute a range of ophthalmic medicines in the region. 12 December 2017
Dealmakers did not have their busiest month in November, potentially due to companies waiting to see the shape of US President Donald Trump's proposed tax cuts. 12 December 2017
Almirall has linked up with US biopharma company Athenex to further develop and commercialize KX-391 for the treatment of actinic keratosis and other skin conditions. 12 December 2017
2017 marks a year of significant advancement for Boehringer Ingelheim as it secured a range of external partnerships with the goal of transforming the lives of patients and winning the fight against cancer, the German family-owned drug major has announced. 12 December 2017
USA-based Ardelyx has inked a license agreement providing Shanghai Fosun Pharma with the exclusive rights to develop and commercialize Ardelyx' lead product, tenapanor, in China for the treatment of patients with irritable bowel syndrome with constipation (IBS-C) and for the treatment of hyperphosphatemia related to chronic kidney disease. 11 December 2017
It is the third-most common disorder in the world. In the USA, close to 38 million people suffer from it. Globally, the number is a whopping 1 billion. We are talking about migraine, also often referred to as ‘super headaches’ — a condition more prevalent than diabetes, epilepsy, and asthma combined. 11 December 2017
The US lobby group Pharmaceutical Research and Manufacturers of America (PhRMA) has initiated litigation in the US District Court for the Eastern District of California challenging SB 17, describing it as ‘an unprecedented and unconstitutional California law.’ 11 December 2017
Drug imports by Russia for the period of January-September of 2017 grew for the first time since 2014 and amounted to 108.700 tonnes, which is 6.5% more than in the same period a year ago. 11 December 2017
Tokyo’s Takeda Pharmaceutical and US-based Seattle Genetics presented positive data from the Phase III ECHELON-1 study of Adcetris (brentuximab vedotin) at the American Society of Hematology (ASH) meeting yesterday. 11 December 2017
A survey compiled by US consulting firm the Reputation Institute put Bayer in the top 10 of a list of the world’s most reputable pharma companies. 11 December 2017
In an oral presentation at the ongoing American Society of Hematology (ASH) meeting, Johnson & Johnson’s pharmaceutical arm Janssen has described a new analysis of data from Phase II and III studies into Imbruvica (ibrutinib). 11 December 2017
Among last week’s most interesting news were two acquisition deals in the field of immuno-oncology: Gilead Sciences buy of Cell Design Labs and bluebird bio’s takeover of Scottish firm TC BioPharm. Gilead also added to the news flow, in that the first patient has been dosed with its newly-approved lymphoma drug Yescarta by the Moffitt Cancer Center. On the licensing front, Collegium Pharmaceuticals acquired rights to Nucynta and Juno Therapeutics lined up with Eli Lilly, taking the US pharma major into the immuno-oncology arena. 10 December 2017
The news early Friday morning that Britain and the European Union had finally agreed that enough progress has been made in the Brexit talks for the UK to leave the EU, to move on to more detailed trade agreement discussions, was broadly welcomed by the pharma and biotech industry. 8 December 2017
Pharmaceuticals and healthcare industry monitor Bioethics International has published its Good Pharma Scorecard, ranking pharmaceutical companies and new drugs on their clinical trial transparency. 8 December 2017
In a reversal of its earlier draft decision, the UK’s health technology assessor has provided final draft guidance recommending Eisai’s Kisplyx (lenvatinib), in combination with everolimus, as an option for treating kidney cancer. 8 December 2017
A report from advocacy group AARP - the American Association of Retired Persons - has found that retail prices for 768 prescription drugs commonly used by older adults increased by an average of 6.4% in 2015, despite a low inflation rate of 0.1% for the period. 7 December 2017
The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines for breast cancer, providing a boost to Novartis' Kisqali (ribociclib). 24 October 2024
Alpha-9 Oncology, a Canadian radiopharmaceutical company, has raised $175 million in an oversubscribed series C financing round led by Lightspeed Venture Partners and Ascenta Capital. 24 October 2024
The US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practice (ACIP) voted to expand its recommendation for the use of certain pneumococcal vaccines, including Prevnar 20 (20-valent pneumococcal conjugate vaccine) for all adults aged 50 and older. 24 October 2024
Sino-America clinical-stage biotech Eccogene announced that it will receive a $60 million payment from AstraZeneca, which is being triggered by successfully achieving milestones related to the development of ECC5004/AZD5004 including the first patient dosed in the Phase IIb program. 24 October 2024
Swiss pharma giant Roche this morning reported that, in the first nine months of 2024 group sales increased by 6% at CER (2% in francs) to 45.0 billion francs ($52.0 billion). 23 October 2024
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 23 October 2024
Shares of Swedish drugmaker Camurus fell almost 10% to 588.50 kroner yesterday after it revealed that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the new drug application (NDA) for CAM2029 (octreotide) extended-release injection for the treatment of patients with acromegaly. 23 October 2024
The US Department of Health and Human Services (HHS), through the Office of Assistant Secretary for Planning and Evaluation (ASPE), yesterday released new data showing that nearly 1.5 million people with Medicare Part D saved nearly $1 billion in out-of-pocket prescription drugs costs in the first half of 2024 because of the Biden-Harris Administration’s Inflation Reduction Act. 23 October 2024
UK pharma major AstraZeneca’s Alexion Rare Disease unit has received a positive recommendation for Voydeya (danicopan), from the UK’s National Institute for Health and Care Excellence (NICE). 22 October 2024
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has recommended elafibranor 80mg tablets for the treatment of PBC, the drug’s French developer Ipsen announced today. 22 October 2024
Melbourne, Australia-based Telix Pharmaceuticals has announced the launch of Rhine Pharma, a subsidiary aimed at increasing global access to radiopharmaceuticals for cancer treatment and imaging. 22 October 2024
Berlin, Germany-based Ariceum Therapeutics has presented data at the European Association of Nuclear Medicine 2024 conference on its first-in-class radiopharmaceutical drug, 225Ac-satoreotide. 22 October 2024
Philadelphia, USA-based SERB Pharmaceuticals has announced the acquisition of Aurlumyn (iloprost), the only FDA-approved treatment for severe frostbite in the USA. 22 October 2024
The Institute for Clinical and Economic Review (ICER) has released its final report assessing the effectiveness and pricing of key treatments for transthyretin amyloid cardiomyopathy (ATTR-CM). 22 October 2024
Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomized trial compared oral semaglutide to placebo as an adjunct to standard of care for the prevention of major adverse cardiovascular events (MACE). 21 October 2024
Sweden-based OncoZenge has announced the intention to partner with UK-based specialty pharma Pharmanovia to secure exclusive rights to commercialize BupiZenge in Europe, the Middle East, and Northern Africa (EMENA). 21 October 2024
Gilead Sciences and Merck & Co have announced new results from a Phase II clinical study evaluating the investigational combination of islatravir, an investigational nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a first-in-class HIV-1 capsid inhibitor. 21 October 2024
Trade group the Association of the British Pharmaceutical Industry (ABPI) has had its say on UK government plans to overhaul the National Health Service (NHS). 21 October 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
Dewpoint is a biotech company pioneering the application of biomolecular condensate biology – the science studying the organization of biomolecules within membrane-less compartments – towards the development of a new generation of therapeutics to address diseases of high unmet need.